Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline

BMC Gastroenterology

Christopher D Byrne¹  Sarah H Wild⁴  Seonwoo Kim³  Sookyoung Woo³  Dong-il Park²  Yong-Kyun Cho²  Bum-Soo Kim⁵  Ki-Chul Sung⁶ 

[1] Endocrinology and Metabolism Unit, University of Southampton, IDS Building, Southampton General Hospital, MP 887, Tremona Road, Southampton, UK, SO166YD;Division of Gastroenterology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;Biostatistics Team, Samsung Biomedical Research Institute, Seoul, Republic of Korea;Centre for Population Health Sciences, University of Edinburgh, IDS Building, Southampton General Hospital, MP 887, Southampton, UK;Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;Division of Cardiology, Kangbuk Samsung, Hospital, Sungkyunkwan University School of Medicine, #108, Pyung Dong, Jongro-Ku, Seoul, 110-746, Republic of Korea

关键词: Metabolic syndrome;    Risk prediction;    Etiology;    Fatty liver;    Non alcoholic fatty liver disease;   

Others  :  1113013
DOI  :  10.1186/1471-230X-12-84

 received in 2011-11-24, accepted in 2012-06-28,  发布年份 2012

【 摘 要 】

Background

Non alcoholic fatty liver disease (NAFLD) is associated with increased risk of type 2 diabetes and chronic liver disease but identifying patients who have NAFLD without resorting to expensive imaging tests is challenging. In order to help identify people for imaging investigation of the liver who are at high risk of NAFLD, our aim was to: a) identify easily measured risk factors at baseline that were independently associated with incident fatty liver at follow up, and then b) to test the diagnostic performance of thresholds of these factors at baseline, to predict or to exclude incident fatty liver at follow up.

Methods

2589 people with absence of fatty liver on ultrasound examination at baseline were re-examined after a mean of 4.4 years in a Korean occupational cohort study. Multi-variable logistic regression analyses were used to identify baseline factors that were independently associated with incident fatty liver at follow up. The diagnostic performance of thresholds of these baseline factors to identify people with incident fatty liver at follow-up was assessed using receiver operating characteristic (ROC) curves.

Results

430 incident cases of fatty liver were identified. Several factors were independently associated with incident fatty liver: increased triglyceride (per mmol/l increase) OR 1.378 [95%CIs 1.179, 1.611], p < 0.0001; glucose (per mmol/l increase) OR 1.215 [95%CIs 1.042, 1.416], p = 0.013; waist (per cm increase) OR 1.078 [95%CIs 1.057, 1.099], p < 0.001; ALT (per IU/L increase) OR 1.009 [95%CIs 1.002, 1.017], p = 0.016; and platelets (per 1x10⁹/L increase) OR 1.004 [1.001, 1.006], p = 0.001; were each independently associated with incident fatty liver. Binary thresholds of the five factors were applied and the area under the ROC curve for incident fatty liver was 0.75 (95%CI 0.72–0.78) for the combination of all five factors above these thresholds.

Conclusion

Simple risk factors that overlap considerably with risk factors for type 2 diabetes allow identification of people at high risk of incident fatty liver at who use of hepatic imaging could be targeted.

【 授权许可】

   
2012 Sung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003, 124:71-79.
• [2]Clark JM, Diehl AM: Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology 2003, 124:248-250.
• [3]Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ: Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008, 14:2474-2486.
• [4]Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
• [5]Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G: Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30:2119-2121.
• [6]Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
• [7]Holt HB, Wild SH, Wood PJ, Zhang J, Darekar AA, Dewbury K, Poole RB, Holt RI, Phillips DI, Byrne CD: Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006, 49:141-148.
• [8]Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
• [9]Prati D, Taioli E, Zanella A, Della TE, Butelli S, Del VE, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
• [10]Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT: Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999, 276:E977-E989.
• [11]Cassidy FH, Yokoo T, Aganovic L, Hanna RF, Bydder M, Middleton MS, Hamilton G, Chavez AD, Schwimmer JB, Sirlin CB: Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 2009, 29:231-260.
• [12]Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH: Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009, 116:539-564.
• [13]Handberg A, Hojlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H: Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012, 271:294-304.
• [14]Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B: Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
• [15]Wang PW, Hsieh CJ, Psang LC, Cheng YF, Liou CW, Weng SW, Chen JF, Chen IY, Li RH, Eng HL: Fatty liver and chronic inflammation in Chinese adults. Diabetes Res Clin Pract 2008, 81:202-208.
• [16]Bedogni G, Kahn HS, Bellentani S, Tiribelli C: A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98. BioMed Central Full Text
• [17]Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33. BioMed Central Full Text
• [18]Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstrale M, Groop L, Orho-Melander M, Yki-Jarvinen H: Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137:865-872.
• [19]Chalasani N: Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time! Gastroenterology 2009, 137:772-775.
• [20]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [21]Saverymuttu SH, Joseph AE, Maxwell JD: Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986, 292:13-15.
• [22]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [23]Youden WJ: Index for rating diagnostic tests. Cancer 1950, 3:32-35.
• [24]Wang J, Stancakova A, Kuusisto J, Laakso M: Identification of undiagnosed type 2 diabetic individuals by the finnish diabetes risk score and biochemical and genetic markers: a population-based study of 7232 Finnish men. J Clin Endocrinol Metab 2010, 95:3858-3862.
• [25]Jesri A, Okonofua EC, Egan BM: Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2005, 7:705-711.
• [26]Ripoche J: Blood platelets and inflammation: Their relationship with liver and digestive diseases. Clin Res Hepatol Gastroenterol 2011, 35:353-357.
• [27]Semple JW, Italiano JE, Freedman J: Platelets and the immune continuum. Nat Rev Immunol 2011, 11:264-274.
• [28]Adams LA: Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011, 26:802-809.
• [29]van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J: Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1 H MR spectroscopy. Radiology 2010, 256:159-168.
• [30]Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, Torella R, Persico M: The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006, 38:485-489.
• [31]Tsuneto A, Hida A, Sera N, Imaizumi M, Ichimaru S, Nakashima E, Seto S, Maemura K, Akahoshi M: Fatty liver incidence and predictive variables. Hypertens Res 2010, 33:638-643.